Results 51 to 60 of about 92,046 (305)

Low-to-Moderate Arsenic Exposure and Urothelial Tract Cancers with a Long Latent Period of Follow-Up in an Arseniasis Area

Journal of Epidemiology and Global Health, 2023
Background Arsenic exposure can cause adverse health effects. The effects of long-term low-to-moderate exposure and methylations remain unclear. Objective This study aims to examine the association between low-to-moderate arsenic exposure and urothelial ...
Pei-Ju Liao, Chih-Hung Lee, Shu-Li Wang, Hung-Yi Chiou, Chien-Jen Chen, Chen-June Seak, I-Wen Wu, Kuang-Hung Hsu   +7 more
doaj   +1 more source

The Role of MMP-9 and VEGF in the Invasion State of Bladder Urothelial Carcinoma

Indonesian Biomedical Journal, 2021
BACKGROUND: Bladder cancer is the tenth-most common cancer in worldwide and the majority are urothelial carcinomas. The depth of invasion plays important role in the prognostic and therapeutic factor in urothelial carcinomas.
Novalia Chumaladewi Guntarno, Anny Setijo Rahaju, Nila Kurniasari   +2 more
doaj   +1 more source

Vaginal cuff recurrence after radical cystectomy: an under - studied site of bladder cancer relapse [PDF]

, 2017
Vaginal cuff recurrence of tumor following radical cystectomy is a rare site of disease recurrence, however it has never been specifically studied. The aim of the study is to evaluate incidence, risk factors, and long-term oncologic outcomes of vaginal ...
Boorjian, Stephen A, Frank, Igor, Karnes, R Jeffrey, Morlacco, Alessandro, Nehra, Avinash, Thapa, Prabin, Zattoni, Fabio   +6 more
core   +1 more source

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

FEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold, Janik Riese, Lancelot Seillier, Mark Kühnel, Julia Pannhausen, Charlotte O. J. Fröhlich, Christian Martin, Peter Boor, Matthias Saar, Danny D. Jonigk, Nadine T. Gaisa, Michael Rose   +11 more
wiley   +1 more source

Quantitative proteomic analysis reveals different characteristics of bladder cancer cells after exposure to bisphenol A

FEBS Open Bio, EarlyView.
Bisphenol A (BPA), a common chemical in plastics, exerts dual effects on bladder cancer cells: low doses promote growth and migration, while high doses suppress growth and migration. Multi‐omics and bioinformatics reveal BPA acts via MAPK and inflammatory pathways.
Shaomin Niu, Lanlan Li, Wenjuan Jia, Hanzhong Feng, Xiaoquan Yu, Youli Zhao, Fengzhi Yuan, Hui Ding, Junqiang Tian, Yong‐Xing He, Zhiping Wang   +10 more
wiley   +1 more source

Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report

Current Oncology
A 48-year-old woman without obvious environmental risk factors was diagnosed with metastatic urothelial carcinoma harboring a mutation in EGFR typical of driver mutations for non-small cell lung cancer.
Sareen T. Ali, David J. VanderWeele
doaj   +1 more source

Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome

Arthritis Care &Research, EarlyView.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino, Grant W. Cannon, Brian C. Sauer, Jorge Rojas, Gregory J. Stoddard, Gary A. Kunkel, Jessica A. Walsh, Bryant R. England, Joshua F. Baker, Tawnie J. Braaten   +9 more
wiley   +1 more source

Impact of urothelial carcinoma with divergent differentiation on tumor stage

Journal of Pathology of Nepal, 2016
Background: Urinary bladder cancer is classified as urothelial or non-urothelial. Ninenty percent of bladder cancer are urothelial and has propensity for divergent differentiation.
S Chalise, A Jha, PR Neupane, SB Pradhan, R Pathak   +4 more
doaj   +1 more source

Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice [PDF]

, 2014
Although somatic mutations and overexpression of the tyrosine kinase fibroblast growth factor receptor 3 (FGFR3) are strongly associated with bladder cancer, evidence for their functional involvement in the pathogenesis remains elusive.
Ahmad, Ahmad, Ahmad, Askham, Billerey, Brooks, Calderaro, Castillo-Martin, Chesi, Cho, Duenas, Dupuy, Gavine, Goetz, Guagnano, Herr, Iwata, Iwata, Iwata, Jebar, Juanpere, Knowles, Kompier, Kong, Korkolopoulou, Laederich, Lamont, Lamy, Lesche, Lindgren, Logie, Lopez-Knowles, Mo, Novak, Platt, Puzio-Kuter, Qing, Rhijn, Ross, Shin, Sjodahl, Stenzl, Tomlinson, Tomlinson, Tsuruta, Yohn, Yoo, Zhang, Zieger   +48 more
core   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source